Top Biotech Companies in Kolkata (13)
Invati Creations Private Limited is in the field of innovation and manufacturing of chemicals with cutting-edge nanotechnology innovations serving various domains. The application of chemical science with the purpose for advancement of science and technology. We have decades of experience in nanotechnology for scaled up synthesis of nano-materials. Our state of art nanotechnology enables making nano-structured Li-ion electrode materials for...
Lupin is a global pharmaceutical company offering Branded and Generic Formulations, Biosimilars and Active Pharmaceutical Ingredients (APIs). Founded over 50 years ago, Lupin today is a significant player in the US, India and Japan and additionally in other counties within APAC, EMEA and LATAM. It holds a global leadership position in Anti-TB and Cephalosporin segments. Today Lupin is focused on...
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
We are one of the fastest growing pharmaceutical company in Eastern India. We are a Manufacturing, Marketing, Wholesaling and Retailing company.dna Aurio Pharma Laboratories Private Limited is focused in achieving excellence in the healthcare business through “customer satisfaction”. Maintaining high standard of safety, quality, productivity and innovation acts as the guiding force for the members of the company.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
The company started its operation in the year 1945 under the leadership of its founder, Mr. Gour Gopal Saha. Initially known as the Standard Medical Research Institute, the company quickly earned its reputation as one of the most innovative organizations in India. The name was later abridged to Stadmed. It is a name widely recognized today for its pioneering pharmaceuticals. It...
Jupiter Pharmaceuticals Ltd, the first company of Dr. Sarkar Allen Group, is in operation since 1969. It is engaged in the manufacturing and marketing of Ayurvedic and Pharmaceuticals products through ethical promotion. Jupiter is proud to be the harbinger of the conglomerate. Care, Commitment and Concern; the corporate mantra of the conglomerate were taken into consideration at the very outset and...
SynBiogenesis is a multidimensional Biotech Skill Development and R&D hub, approved by Ministry of Corporate affairs, Government of INDIA by Companies Act 2013 with CIN- U80903WB2022PTC252907and registered under MSME: UDYAM-WB-03-0015244. We are also recognized by DPIIT, Startup India – DIPP99921. We are equipped with international standards lab facilities with modern instrumentation facility. Our Vision and Mission: 1. The promotion of high-level basic research...
About Us GCC Biotech Pvt. Ltd. founded in year 2006, is one of the pioneer biotech research based company in eastern part of India. Since its inception, it has facilitated many researchers, scientists and scholars from various research institutes with its products and services. Within a decade, the company has developed a multi-functional state-of-the-art infrastructure with DSIR recognition and ISO 9001:2008 and...
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
AstraZeneca's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.
Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.
Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
We are a leading Indian pharmaceutical company in Eastern Zone engaged in the product design & development, manufacture and sale of pharmaceutical and nutraceutical products.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...
Roche's Top Stability & Growth Strengths
Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.
Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.
Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.
